[8-K] CONMED Corp Reports Material Event

CONMED Corporation filed a current report to let investors know it has released its financial results for the fourth quarter ended December 31, 2025.

Rhea-AI Filing Summary

CONMED Corporation filed a current report to let investors know it has released its financial results for the fourth quarter ended December 31, 2025. The company issued a press release on January 28, 2026, and attached it as Exhibit 99.1 to this report.

The filing clarifies that the earnings information in Item 2.02 and the press release are being furnished, not filed, which affects how they are treated under securities laws and how they may be incorporated into other regulatory documents.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CONMED Corporation (CNMD) report in its latest 8-K filing?

CONMED Corporation reported that it issued a press release announcing financial results for the fourth quarter ended December 31, 2025. The press release is furnished as Exhibit 99.1, giving investors access to the detailed quarterly results and commentary.

When did CONMED Corporation (CNMD) release its fourth-quarter 2025 financial results?

CONMED Corporation released its fourth-quarter 2025 financial results on January 28, 2026. On that date, it issued a press release covering the quarter ended December 31, 2025, and furnished that release as Exhibit 99.1 to a Form 8-K current report.

What is Exhibit 99.1 in CONMED Corporation’s (CNMD) January 2026 8-K?

Exhibit 99.1 is a press release dated January 28, 2026, issued by CONMED Corporation. It contains the company’s financial results for the fourth quarter ended December 31, 2025, providing detailed performance information beyond the brief description in the 8-K body.

How are CONMED Corporation’s (CNMD) fourth-quarter results treated under securities laws?

The fourth-quarter results and related press release are furnished, not filed, under Item 2.02 of the 8-K. This means they are not subject to certain liabilities under Section 18 of the Securities Exchange Act and are only incorporated into other filings if specifically referenced.

Which period do the financial results in CONMED Corporation’s (CNMD) press release cover?

The financial results in CONMED Corporation’s press release cover the fourth quarter ended December 31, 2025. The company noted this period explicitly in its 8-K, tying the reported performance to the final quarter of its 2025 fiscal year.

Who signed CONMED Corporation’s (CNMD) January 28, 2026 Form 8-K?

The Form 8-K was signed on behalf of CONMED Corporation by Todd W. Garner. He is identified in the filing as Executive Vice President, Finance & Chief Financial Officer, indicating senior financial management’s approval of the furnished information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/28/2026 - 04:13 PM EST Learn about SEC filing dates

FALSE000081695600008169562026-01-282026-01-28

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15 (d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 28, 2026

CONMED CORPORATION

(Exact name of registrant as specified in its charter)

Delaware			001-39218			16-0977505
(State or other jurisdiction of incorporation or organization)			(Commission File Number)			(I.R.S. Employer Identification No.)

11311 Concept Blvd Largo, FL			33773
(Address of principal executive offices)			(Zip code)

(727) 392-6464

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (See General Instruction A.2 below):

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Rule 12(b) of the Act

Title of each class			Trading Symbol			Name of each exchange on which registered
Common Stock, $0.01 par value			CNMD			NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐

Item 2.02    Results of Operations and Financial Condition

On January 28, 2026, CONMED Corporation issued a press release announcing financial results for the fourth quarter ended December 31, 2025. A copy of this press release is attached hereto as Exhibit 99.1.

The information in this Current Report on Form 8-K that is furnished under “Item 2.02. Results of Operations and Financial Condition” and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

Item 9.01    Financial Statements and Exhibits

(d)    Exhibits

The following exhibits are included herewith:

Exhibit No.			Description of Exhibit
99.1			Press release dated January 28, 2026, issued by CONMED Corporation.
104			Cover Page Interactive Data File (embedded within the Inline XBRL Document).

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                    

Date: January 28, 2026			CONMED CORPORATION
			(Registrant)

By:			/s/ Todd W. Garner
Name:			Todd W. Garner
Title:			Executive Vice President, Finance & Chief Financial Officer